The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a
| Condition(s) | Irritable Bowel Syndrome |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. The two main mechanisms invoking IBS development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.Yet to date, a person-specific elucidation of the specific small |
| Who can participate | Inclusion Criteria: * Male and Female * Age - 18-70 Exclusion Criteria: * Consumption of antibiotics 2 months prior to the first day of the experiment. * Consumption of probiotic supplements 1 month prior to the first day of the experiment. * Type 1 or type 2 diabetes diagnosis. * Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study. * Chronic disease - to the discretion of the study doctor. * Cancer and recent anticancer treatment. * Psychiatric disorders - to the discretion of the study doctor. * IBD (inflammatory bowel diseases). * Alcohol or substance abuse. * BMI \> 35. |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Weizmann Institute of Science |
| Locations | Rehovot, Israel |
| Start date | 2026-05-11 |
| NCT ID | NCT05972317 |
| Official listing | https://clinicaltrials.gov/study/NCT05972317 |